Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer
Ken Imaizumi(Hokkaido University), Tetsuya Nakatsura(Unknown), Yuji Nishizawa(National Cancer Center Hospital East), Masaaki Ito(National Cancer Centre Japan), Manami Shimomura(National Cancer Center Hospital East), Naoki Sakuyama(National Cancer Center Hospital East), Motohiro Kojima(Chiba Cancer Center), Akinobu Taketomi(Hokkaido University), Yuichiro Tsukada(National Cancer Center Hospital East), Toshihiro Suzuki(National Cancer Center Hospital East), Takeshi Sasaki(Sapporo Medical University)
Cited by 39
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244